Cargando…
One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics
Tuberculosis (TB) remains a global health problem despite almost universal efforts to provide patients with highly effective chemotherapy, in part, because many infected individuals are not diagnosed and treated, others do not complete treatment, and a small proportion harbor Mycobacterium tuberculo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008060/ https://www.ncbi.nlm.nih.gov/pubmed/33796474 http://dx.doi.org/10.3389/fcimb.2021.613149 |
_version_ | 1783672621433356288 |
---|---|
author | Yang, Hee-Jeong Wang, Decheng Wen, Xin Weiner, Danielle M. Via, Laura E. |
author_facet | Yang, Hee-Jeong Wang, Decheng Wen, Xin Weiner, Danielle M. Via, Laura E. |
author_sort | Yang, Hee-Jeong |
collection | PubMed |
description | Tuberculosis (TB) remains a global health problem despite almost universal efforts to provide patients with highly effective chemotherapy, in part, because many infected individuals are not diagnosed and treated, others do not complete treatment, and a small proportion harbor Mycobacterium tuberculosis (Mtb) strains that have become resistant to drugs in the standard regimen. Development and approval of new drugs for TB have accelerated in the last 10 years, but more drugs are needed due to both Mtb’s development of resistance and the desire to shorten therapy to 4 months or less. The drug development process needs predictive animal models that recapitulate the complex pathology and bacterial burden distribution of human disease. The human host response to pulmonary infection with Mtb is granulomatous inflammation usually resulting in contained lesions and limited bacterial replication. In those who develop progressive or active disease, regions of necrosis and cavitation can develop leading to lasting lung damage and possible death. This review describes the major vertebrate animal models used in evaluating compound activity against Mtb and the disease presentation that develops. Each of the models, including the zebrafish, various mice, guinea pigs, rabbits, and non-human primates provides data on number of Mtb bacteria and pathology resolution. The models where individual lesions can be dissected from the tissue or sampled can also provide data on lesion-specific bacterial loads and lesion-specific drug concentrations. With the inclusion of medical imaging, a compound’s effect on resolution of pathology within individual lesions and animals can also be determined over time. Incorporation of measurement of drug exposure and drug distribution within animals and their tissues is important for choosing the best compounds to push toward the clinic and to the development of better regimens. We review the practical aspects of each model and the advantages and limitations of each in order to promote choosing a rational combination of them for a compound’s development. |
format | Online Article Text |
id | pubmed-8008060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80080602021-03-31 One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics Yang, Hee-Jeong Wang, Decheng Wen, Xin Weiner, Danielle M. Via, Laura E. Front Cell Infect Microbiol Cellular and Infection Microbiology Tuberculosis (TB) remains a global health problem despite almost universal efforts to provide patients with highly effective chemotherapy, in part, because many infected individuals are not diagnosed and treated, others do not complete treatment, and a small proportion harbor Mycobacterium tuberculosis (Mtb) strains that have become resistant to drugs in the standard regimen. Development and approval of new drugs for TB have accelerated in the last 10 years, but more drugs are needed due to both Mtb’s development of resistance and the desire to shorten therapy to 4 months or less. The drug development process needs predictive animal models that recapitulate the complex pathology and bacterial burden distribution of human disease. The human host response to pulmonary infection with Mtb is granulomatous inflammation usually resulting in contained lesions and limited bacterial replication. In those who develop progressive or active disease, regions of necrosis and cavitation can develop leading to lasting lung damage and possible death. This review describes the major vertebrate animal models used in evaluating compound activity against Mtb and the disease presentation that develops. Each of the models, including the zebrafish, various mice, guinea pigs, rabbits, and non-human primates provides data on number of Mtb bacteria and pathology resolution. The models where individual lesions can be dissected from the tissue or sampled can also provide data on lesion-specific bacterial loads and lesion-specific drug concentrations. With the inclusion of medical imaging, a compound’s effect on resolution of pathology within individual lesions and animals can also be determined over time. Incorporation of measurement of drug exposure and drug distribution within animals and their tissues is important for choosing the best compounds to push toward the clinic and to the development of better regimens. We review the practical aspects of each model and the advantages and limitations of each in order to promote choosing a rational combination of them for a compound’s development. Frontiers Media S.A. 2021-03-16 /pmc/articles/PMC8008060/ /pubmed/33796474 http://dx.doi.org/10.3389/fcimb.2021.613149 Text en Copyright © 2021 Yang, Wang, Wen, Weiner and Via http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Yang, Hee-Jeong Wang, Decheng Wen, Xin Weiner, Danielle M. Via, Laura E. One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics |
title | One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics |
title_full | One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics |
title_fullStr | One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics |
title_full_unstemmed | One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics |
title_short | One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics |
title_sort | one size fits all? not in in vivo modeling of tuberculosis chemotherapeutics |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008060/ https://www.ncbi.nlm.nih.gov/pubmed/33796474 http://dx.doi.org/10.3389/fcimb.2021.613149 |
work_keys_str_mv | AT yangheejeong onesizefitsallnotininvivomodelingoftuberculosischemotherapeutics AT wangdecheng onesizefitsallnotininvivomodelingoftuberculosischemotherapeutics AT wenxin onesizefitsallnotininvivomodelingoftuberculosischemotherapeutics AT weinerdaniellem onesizefitsallnotininvivomodelingoftuberculosischemotherapeutics AT vialaurae onesizefitsallnotininvivomodelingoftuberculosischemotherapeutics |